Not Signed In -
Nucleoside Analogues |
|
|
Clinical Trial: A 48 week study comparing treatment with saquinavir + lopinavir/ritonavir in combination with enfuvirtide HAART versus saquinavir + lopinavir/ritonavir + other nucleoside combinations to see the efficacy of these treatments in patients infected with HIV-1
This study is currently recruiting patients.
|
Purpose
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| HIV | Drug: enfuvirtide | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- CD4 cell count > 50 cells/mm3
- HIV - 1 RNA viral load >/= 5000 copies/mL
- Patients must be HIV treatment experienced
- Patients diagnosed with HIV - 1 infection
Exclusion Criteria:
- Female patients must not be able to have children or under effective contraceptives
- Female patients who are pregnant
- have taken enfuvirtide and/or T-1249 before
- have serious kidney problems
- alcohol and/or drug abuse
- have had an organ transplant
Location and Contact Information
Please reference Study ID Number: RLI-ML18021 973-235-5000
or 800-526-6367 (FOR US ONLY)
or 800-526-6367 (FOR US ONLY)
Alabama
Hobson City, Alabama, 36201, United States; Recruiting
California
Los Angeles, California, 90069, United States; Recruiting
Los Angeles, California, 90033, United States; Not yet recruiting
District of Columbia
Washington, District of Columbia, 20009, United States; Recruiting
Washington, District of Columbia, 20007, United States; Recruiting
Florida
Altamonte Springs, Florida, 32701, United States; Recruiting
Georgia
Atlanta, Georgia, 30308, United States; Recruiting
Macon, Georgia, 31201, United States; Recruiting
Illinois
Chicago, Illinois, 60657, United States; Recruiting
Chicago, Illinois, 80612, United States; Recruiting
Maryland
Baltimore, Maryland, 21201, United States; Recruiting
Massachusetts
Boston, Massachusetts, 02215, United States; Recruiting
Mississippi
Jackson, Mississippi, 39216, United States; Recruiting
Missouri
St. Louis, Missouri, 63139, United States; Recruiting
New Jersey
Newark, New Jersey, 07103, United States; Recruiting
New York
New York, New York, 10011, United States; Recruiting
New York, New York, 10016, United States; Recruiting
North Carolina
Huntersville, North Carolina, 28078, United States; Recruiting
Texas
Houston, Texas, 77004, United States; Recruiting
Dallas, Texas, 75246, United States; Recruiting
More Information
Study ID Numbers: ML18021
Record last reviewed: April 2005
Last Updated: April 6, 2005
Record first received: January 7, 2005
ClinicalTrials.gov Identifier: NCT00100984
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: April 2005
Last Updated: April 6, 2005
Record first received: January 7, 2005
ClinicalTrials.gov Identifier: NCT00100984
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
email this page
print this page
bookmark this page
feedback on this page
